Hemab Therapeutics vs Saluda Medical
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $157M oversubscribed Series C (Oct 2025) led by Sofinnova and Qatar Investment Authority. Sutacimig entering registration study 2026 for Glanzmann thrombasthenia — zero approved prophylactics.
About
Hemab Therapeutics is a rare disease biotechnology company developing treatments for rare bleeding disorders that have no approved prophylactic options. The company raised $157 million in an oversubscribed Series C in October 2025, led by Sofinnova Partners and the Qatar Investment Authority (QIA) — a sovereign wealth fund's direct biotech investment signals strategic medical technology interest alongside financial return.
Saluda Medical is the pioneer of closed-loop spinal cord stimulation (SCS); FDA-approved Evoke SCS system with real-time neural feedback; raised $100M in Jan 2025; received FDA clearance for automated EVA programming platform.
About
Saluda Medical is a commercial-stage medical device company that has pioneered closed-loop neuromodulation therapy for chronic pain management. Headquartered in Macquarie Park, Australia (with US operations in Marlborough, Massachusetts), Saluda''s flagship product is the Evoke Spinal Cord Stimulation (SCS) System — the world''s first SCS system that senses and measures neural responses to stimulation (evoked compound action potentials, or ECAPs) and automatically adjusts therapy in real time based on each patient''s neurophysiological feedback. This closed-loop approach provides more precise, consistent pain relief compared to conventional open-loop SCS systems.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.